Resverlogix Featured on BNN Business Day with Frances Horodelski

Donald McCaffrey, President and CEO of Resverlogix will appear live on BNN’s Business Day with Frances Horodelski on April 22 at 10:15 am ET. Tune in to watch the live interview!

Here is a link to the show Business Day:

New Analyst Report: Zacks Small-Cap Research Initiated Coverage on RVX

Zacks Small-Cap Research initiated coverage on Resverlogix on April 20, 2015. The report entitled: “RVX: Initiating Coverage of Resverlogix Corp.; A Clinical Stage Cardiovascular Company with an Epigenetics Platform,” published today by Jason Napodano, CFA and Nisha Hirani, MD.

Contact information:
Jason Napodano, CFA

New Analyst Report: Analysis of the Science Behind RVX-208

Published today on Seeking Alpha, Bjarke Krysel Christensen authored a report on Resverlogix entitled: “Analysis of the Science Behind RVX-208”.


Resverlogix in Life Science Leader: Companies to Watch

Yesterday, Resverlogix was featured in the “Life Science Leader – Companies to Watch” by Wayne Koberstein, Executive Editor @WayneKoberstein.

“This 14-year-old company patiently stacks up clinical evidence of health benefits gained from oral treatments with a new, epigenetic MOA (mechanism of action) for long-neglected, large-market chronic diseases.”

To access the full report, please click here:

ACC.15 Highlight, CVD & Epigenetics

The American College of Cardiology Annual Scientific Session and Expo is one of the most important cardiology conferences. Each year, interesting news is announced and scientific findings are presented over the course of three days. This year’s conference was held in San Diego on March 14-16. Periodically, Resverlogix will blog on topics held at major conferences.

The final presentation of the first day detailing the state of the art in vascular biology was delivered by Dr. Jorge Plutzky, associate professor at Harvard Medical School and director of the Vascular Disease Prevention Program. He presented his work on the role transcription factors play in determining cardiovascular disease (CVD) risks in patients with diabetes mellitus (DM). He showed data pointing to the role of both the peroxisome proliferator-activated receptors (PPAR) and retinoid X receptor (RXR) as the coordinators of cell signaling that enables blood vessel damage in patients with diabetes and CVD. Blood vessel damage is one of the first stages in development of cardiovascular disease and this damage can eventually lead to events like heart attacks and strokes.

In the last segment of his presentation Dr. Plutzky detailed how epigenetics may be responsible for coordinating a multitude of genes leading to the development of vascular disease. He described how pro-inflammatory signals rapidly activate specific intracellular proteins, which in turn can lead to blood vessel disease. He also described the role of bromodomain extra-terminal (BET) proteins and specifically BRD2 in blood vessel disease. He noted that use of a BET inhibitor reduced markers for CVD in an animal model of DM, opening new possibilities for use of epigenetic drugs in the treatment of people with CVD and DM.

Further reading:
Brown et al. Molecular Cell (2014) 56: 219-231

Dr. Norman Wong presents at EAS Congress, Glasgow, Scotland

Dr. Norman CW Wong, CSO of Resverlogix presented data on RVX-208 at the European Atherosclerosis Society (EAS) annual meeting in an oral abstract entitled: “RVX-208 a selective bromodomain extra-terminal protein inhibitor reduces MACE in patients with high residual risks of cardiovascular disease, a post-hoc analysis”.

Resverlogix’s Phase 2b clinical trials SUSTAIN and ASSURE revealed that treatment with RVX-208 lead to a marked reduction in major adverse cardiac events (MACE). The addition of RVX-208 (200 mg/day) on top of standard of care therapy including optimal doses of statins in SUSTAIN and ASSURE raised levels of ApoA-I/HDL-c in treated patients.

These changes alone are unlikely to explain the observed MACE reduction. In the search for potential explanations, levels of more than 60 plasma biomarkers were measured in clinical samples collected in the two trials. One of the significant findings was that RVX-208 lowered glucose in patients with diabetes mellitus (DM) who also had low levels of HDL. This finding is intriguing because there are many patients with DM who have low HDL and high CVD risk thus they would benefit from the actions of RVX-208. Furthermore, this glucose lowering action of RVX-208 goes hand in hand with the preliminary observations from our recent trial of subjects with pre-diabetes mellitus completed in Australia.

The presentation also included state-of-the-art microarray data. This technology is a powerful approach to look at how RVX-208 may be beneficial for CVD beyond that provided by biomarker measurements. The technology allows us to analyze and survey thousands of genes for effects of RVX-208. The data collected from primary human hepatocytes showed that RVX-208 attenuated activity of genes in cellular pathways or networks for inflammation, coagulation, complement, cholesterol synthesis and glucose metabolism.

This data reflects our leadership role in understanding selective BET inhibition by RVX-208 in both humans and at the cellular level. The marked reductions of MACE in SUSTAIN and ASSURE provides the foundation for the Company’s planned Phase 3 clinical trial called BETonMACE. The microarray data is most exciting because it provides, at a cellular level, novel insights that detail the multiple activities of RVX-208 beyond its ApoA-I effects in lowering MACE.

Norman Wong Presentation at EAS Congress 2015

Resverlogix Exclusive in BioSpace Breaking News

Today Resverlogix was featured in BioSpace Breaking News: EXCLUSIVE: Resverlogix Corporation (RVX.TO) CEO Says Experimental Cardiac Drug Holds High Hopes, As Biotech Booms, reported by Riley McDermid, Breaking News Sr. Editor, BioSpace.

Here is an excerpt from the article:

“The boom in the biotech sector has been uplifting to the entire industry,” said McCaffrey. “The goal of the industry is to help patients and to treat diseases more effectively and with less toxicities. The more research, the higher the level of understanding about the biology behind diseases, the better our medicines will be.”

You can read the full article here:

New Analyst Coverage on Resverlogix

A new analyst report has been published covering the cost benefits of RVX-208 and discussing our single epigenetic target with effects on multiple synchronized biological pathways.

Marcel Wijma, chief research analyst at Van Leeuwenhoeck Research (VLR) initiated coverage on Resverlogix on March 16, 2015 in a new report entitled: “Epigenetics & Select BET Inhibition. A new approach to high risk diabetes and chronic kidney disease.” Contact info:

Resverlogix 2015 Outlook: A Video Message from Donald McCaffrey, President & CEO

Thanks to the collaboration with Executive Video during the JP Morgan Annual Healthcare Conference last month in San Francisco, CA., we are able to provide a company overview and share our focus for 2015.

Resverlogix Corp. also presented on January 14 at Biotech Showcase 2015 during JP Morgan week. Click here to view the archived presentation.

For additional updates, please follow us on Twitter: @Resverlogix_RVX and YouTube: ResverlogixRVX 

Year in Review: Onwards & Upwards

Thank you for your continued support of Resverlogix over the last year! Drug development can be a rocky road but we are still going strong. This past year has been a whirlwind of events as we have had lots of progress with new data (77% relative risk reduction in MACE in patients with diabetes mellitus (DM)), the addition of Dr. Mike Sweeney to senior management and being featured in various publications/posters including: PNAS, Cell, PLOS One, Atherosclerosis, SciBX, ACC (Cleveland Clinic poster presentation), ESC (presented in ‘State of the Art and Featured Research Session’), and BioWorld Today (new article today!).

The company was able to identify the target patient population for our next clinical trial – patients with DM, established CVD and HDL-c less than 40mg/dL. Resverlogix is on track to commence this clinical trial in the first half of 2015! With the recent receipt of additional funding we are set to move forward.

Resverlogix on Twitter!

Starting off in the New Year, we will be entering the social media space – Twitter! You can follow us @Resverlogix_RVX for updates and highlights. Also look out in early 2015 for new updates to the website!

Resverlogix on the Road

We will be presenting at the Biotech Showcase 2015 / JP Morgan Annual Healthcare Conference in San Francisco, CA from January 12-14. Our presentation time is on Wednesday, January 14, 2015 at 10:00am PST on the 4th Floor, C – Mission II of the Parc 55 Wyndam Union Square.

To view other conferences that Resverlogix will be participating in, please click here.

Resverlogix in the Media

Resverlogix was mentioned in this morning’s edition of BioWorld Today, ‘Bromo’ seltzer: Merck’s Oncoethix buyout puts renewed fizz into epigenetic strategy.” Access the full story here.

Future Blog Posts

Resverlogix is committed to revitalizing our blog in 2015. We will be detailing our continued interest in epigenetics and how it can be harnessed to help patients with diabetes mellitus, Alzheimer’s disease, chronic kidney disease (CKD) and other indications. If you have a topic you would like us to blog on – please let us know!

Have a safe and happy holiday season! All the best for 2015!

With warm regards,
The Resverlogix team